WO2000056303A3 - Treatment of immune diseases - Google Patents

Treatment of immune diseases Download PDF

Info

Publication number
WO2000056303A3
WO2000056303A3 PCT/US2000/007629 US0007629W WO0056303A3 WO 2000056303 A3 WO2000056303 A3 WO 2000056303A3 US 0007629 W US0007629 W US 0007629W WO 0056303 A3 WO0056303 A3 WO 0056303A3
Authority
WO
WIPO (PCT)
Prior art keywords
derivatives
provides
derivative
attenuate
cannabinol
Prior art date
Application number
PCT/US2000/007629
Other languages
French (fr)
Other versions
WO2000056303A2 (en
Inventor
Craig R Travis
Original Assignee
Immugen Pharmaceuticals Inc
Craig R Travis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immugen Pharmaceuticals Inc, Craig R Travis filed Critical Immugen Pharmaceuticals Inc
Priority to BR0009200-2A priority Critical patent/BR0009200A/en
Priority to IL14547000A priority patent/IL145470A0/en
Priority to JP2000606208A priority patent/JP2002539246A/en
Priority to EP00918266A priority patent/EP1189603A2/en
Priority to AU39107/00A priority patent/AU3910700A/en
Priority to CA002367262A priority patent/CA2367262A1/en
Priority to HU0203437A priority patent/HUP0203437A3/en
Publication of WO2000056303A2 publication Critical patent/WO2000056303A2/en
Priority to IL145470A priority patent/IL145470A/en
Publication of WO2000056303A3 publication Critical patent/WO2000056303A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
    • C07C39/08—Dihydroxy benzenes; Alkylated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
    • C07C39/10—Polyhydroxy benzenes; Alkylated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/18—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring
    • C07C39/19—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring containing carbon-to-carbon double bonds but no carbon-to-carbon triple bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/245—Halogenated derivatives monocyclic polyhydroxylic containing halogens bound to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds

Abstract

The present invention provides a method, compounds, and compositions for treating a disease associated with immune dysfunction. In accordance with the method, a pharmacologically-acceptable composition including at least one compound selected from the group of compounds consisting of 5-alkyl-resorcinol derivatives, cannabinol derivatives, cannabidiol derivatives, cannabigerol derivatives, and combinations thereof is administered to a patient under conditions sufficient to attenuate the dysfunction within the immune system. The invention also provides an antiviral cannabinol derivative that can be used in the inventive method. The invention also provides an alkylated resorcinol derivative and a method of using the alkylated resorcinol derivative to attenuate the growth of a neoplasm. The method and compound are useful for treating diseases of the immune system, such as HIV disease and neoplastic disorders.
PCT/US2000/007629 1999-03-22 2000-03-22 Treatment of immune diseases WO2000056303A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BR0009200-2A BR0009200A (en) 1999-03-22 2000-03-22 Compounds and compositions for the treatment of diseases associated with immune dysfunction
IL14547000A IL145470A0 (en) 1999-03-22 2000-03-22 Compositions for the treatment of immune diseases
JP2000606208A JP2002539246A (en) 1999-03-22 2000-03-22 Treatment of immune disorders
EP00918266A EP1189603A2 (en) 1999-03-22 2000-03-22 Treatment of immune diseases like hiv disease and neoplastic disorders
AU39107/00A AU3910700A (en) 1999-03-22 2000-03-22 Treatment of immune diseases
CA002367262A CA2367262A1 (en) 1999-03-22 2000-03-22 Treatment of immune diseases
HU0203437A HUP0203437A3 (en) 1999-03-22 2000-03-22 Use of resorcinol derivatives for producing pharmaceutical compositions for treatment of immune diseases
IL145470A IL145470A (en) 1999-03-22 2001-09-16 Alkylated resorcinol derivatives

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12567499P 1999-03-22 1999-03-22
US15159599P 1999-08-30 1999-08-30
US60/151,595 1999-08-30
US60/125,674 1999-08-30

Publications (2)

Publication Number Publication Date
WO2000056303A2 WO2000056303A2 (en) 2000-09-28
WO2000056303A3 true WO2000056303A3 (en) 2002-01-24

Family

ID=26823816

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/007629 WO2000056303A2 (en) 1999-03-22 2000-03-22 Treatment of immune diseases

Country Status (10)

Country Link
US (1) US6274635B1 (en)
EP (1) EP1189603A2 (en)
JP (1) JP2002539246A (en)
CN (2) CN1377261A (en)
AU (1) AU3910700A (en)
BR (1) BR0009200A (en)
CA (1) CA2367262A1 (en)
HU (1) HUP0203437A3 (en)
IL (2) IL145470A0 (en)
WO (1) WO2000056303A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
AU6088200A (en) * 1999-07-12 2001-01-30 Virginia Commonwealth University Novel vasodilator cannabinoid analogs
US6312474B1 (en) * 1999-09-15 2001-11-06 Bio-Vascular, Inc. Resorbable implant materials
FR2801305B1 (en) * 1999-11-24 2002-12-06 Galderma Res & Dev VITAMIN D ANALOGS
AUPR018900A0 (en) * 2000-09-18 2000-10-12 Fh Faulding Pty Limited Pamidronate solution
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US6974835B2 (en) * 2000-05-17 2005-12-13 Indevus Pharmaceuticals, Inc. Methods for decreasing cell proliferation based on (3r,4r)-Δ8-tetrahydrocannabinol-11-oic acids
IL136839A (en) 2000-06-16 2006-12-10 Yissum Res Dev Co Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same
WO2002013886A2 (en) * 2000-08-15 2002-02-21 University Of Kentucky Research Foundation Programmable multi-dose intranasal drug delivery device
WO2002022136A1 (en) * 2000-09-18 2002-03-21 F H Faulding & Co Limited Diphosphonate solutions
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
US10004684B2 (en) 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
WO2003015700A2 (en) * 2001-08-15 2003-02-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Novel vasoconstrictor cannabinoid analogs
US7351729B2 (en) 2002-03-08 2008-04-01 Signal Pharmaceuticals, Llc JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
WO2003091189A1 (en) * 2002-04-25 2003-11-06 Virginia Commonwealth University Cannabinoids
CN1678303A (en) * 2002-08-23 2005-10-05 康涅狄格大学 Keto cannabinoids with therapeutic indications
IL162636A0 (en) * 2004-06-20 2005-11-20 Yissum Res Dev Co Resorcinol derivatives and their use for lowering blood pressure
USRE46558E1 (en) 2005-04-28 2017-09-26 Paloma Pharmaceuticals, Inc. Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
ZA200802767B (en) * 2005-09-29 2009-09-30 Amr Technology Inc Process for production of delta-9-tetrahydrocannabinol
DE102005062098A1 (en) * 2005-12-22 2007-06-28 Merck Patent Gmbh New oxaphenanthrene derivatives useful as cannabinoid receptor inhibitors, e.g. for treating psychoses, anxiety, depression, aprosexia, memory and cognitive disorders, appetite loss, obesity
US9763894B2 (en) * 2006-12-05 2017-09-19 Virginia Commonwealth University Inflammation therapy
US20080275030A1 (en) * 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
US8293786B2 (en) * 2007-07-30 2012-10-23 Alltranz Inc. Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same
CA2719853A1 (en) * 2008-03-25 2009-10-01 Paloma Pharmaceuticals, Inc. Methods of treating fibrotic disorders
US20120172339A1 (en) * 2009-07-10 2012-07-05 Northeastern University Angiogenic resorcinol derivatives
ES2627682T3 (en) 2009-12-29 2017-07-31 Mapi Pharma Limited Intermediate compounds and processes for the preparation of tapentadol and related compounds
US9381187B2 (en) 2011-02-16 2016-07-05 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
JP2013091612A (en) * 2011-10-25 2013-05-16 Nisshin Seifun Group Inc Immunosuppressant
NL2009671C2 (en) * 2012-10-19 2014-04-23 Fytagoras B V New antiviral use for acidic cannabinoids.
WO2017191630A1 (en) * 2016-05-02 2017-11-09 Stero Biotechs Ltd. Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases
WO2018064654A1 (en) 2016-10-01 2018-04-05 James Smeeding Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
IL268211B2 (en) 2017-02-01 2023-04-01 Gbs Global Biopharma Inc Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
CN109419786B (en) * 2017-08-31 2021-04-30 汉义生物科技（北京）有限公司 Application of cannabidiol in preparation of anti-influenza drugs
US11033527B2 (en) 2018-02-07 2021-06-15 Immugen Pharma Llc Non-hormonal treatment of the genitourinary syndrome of menopause
EP3997095A4 (en) * 2019-07-12 2022-12-28 Canopy Growth Corporation Cannabinoid derivatives
US20230002425A1 (en) * 2020-01-08 2023-01-05 Chengdu Baiyu Pharmaceutical Co., Ltd. Cannabidiol derivatives, preparation method thereof and use thereof
US20240116883A1 (en) 2020-11-24 2024-04-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Cannabinoid derivatives and their use the treatment of inflammation and/or pain and/or obesity

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011668A2 (en) * 1995-09-11 1997-04-03 Yissum Research Development Co. Of The Hebrew University TUMOR NECROSIS FACTOR ALPHA (TNF-α) INHIBITING PHARMACEUTICALS
WO1997040006A2 (en) * 1996-04-19 1997-10-30 Cancer Research Campaign Technology Limited Phosphate mimics
WO1999052524A1 (en) * 1998-04-14 1999-10-21 The Mathilda & Terence Kennedy Institute Of Rheumatology Use of cannabinoids as anti-inflammatory agents
WO1999053917A1 (en) * 1998-04-21 1999-10-28 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Cannabinoids as antioxidants and neuroprotectants
JP2000191520A (en) * 1998-12-31 2000-07-11 Kazuo Sakuma Microbicide

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2509386A (en) 1950-05-30 Debenzopyran marihuana-like
US2304669A (en) 1940-08-16 1942-12-08 Adams Roger Isolation of cannabidiol
US3388136A (en) 1966-01-11 1968-06-11 Edward C. Taylor Dibenzo [b, d] pyrans and process
US3799946A (en) 1972-03-13 1974-03-26 Smithkline Corp Dibenzo(b,d)pyran compounds
DE2335136A1 (en) 1973-07-06 1975-01-16 Schering Ag 7-HYDROXY-DELTA HIGH 8-TETRAHYDROCANNABINOLS
US3856821A (en) 1973-07-18 1974-12-24 Smithkline Corp ALKOXY DIBENZO (b,d) PYRANS
GB1522057A (en) 1975-11-03 1978-08-23 Pfizer 9-hydroxydibenzo(b,d)pyrans and intermediates therefor
US4087545A (en) 1976-02-17 1978-05-02 Eli Lilly And Company Hexahydro-dibenzo[b,d]pyran-9-ones as antiemetic drugs
US4064009A (en) 1976-06-09 1977-12-20 Eli Lilly And Company Novel 3-(oxygenated alkyl)-1,9-dihydroxy and 1-hydroxy-9-keto dibenzo[b,d]py
US4837228A (en) 1979-05-31 1989-06-06 The University Of Mississippi Antiinflammatory and antimicrobial compounds and compositions
US4309545A (en) 1980-07-28 1982-01-05 Pfizer Inc. Oximino-1-hydroxyoctahydrobenzo[c]quinolines and derivatives thereof
HU194858B (en) 1982-12-03 1988-03-28 Chinoin Gyogyszer Es Vegyeszet Process for producing dibenzo/b,d/pirane derivatives and pharmaceutical compositions containing them
DE3305755A1 (en) 1983-02-19 1984-08-23 Gödecke AG, 1000 Berlin N-PHENYL-BENZAMIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN THE FIGHT AGAINST DISEASES OF THE IMMUNE SYSTEM
IL80411A (en) 1986-10-24 1991-08-16 Raphael Mechoulam Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them
US4833073A (en) 1987-01-27 1989-05-23 Hoffmann-La Roche Inc. Immunoassay for tetrahydrocannabinol metabolites
US4758597A (en) 1987-05-15 1988-07-19 University Patents, Inc. Carenadiol and derivatives
US4847290A (en) 1987-08-17 1989-07-11 Sumner Burstein Delta 1-thc-7-oic acid and analgesic and anti-inflammatory agents
US4973603A (en) 1988-06-16 1990-11-27 Sumner Burstein Platelet activating factor antagonist and methods of use therefor
JPH02101036A (en) 1988-10-05 1990-04-12 Yamanouchi Pharmaceut Co Ltd Alkylbenzene derivative and medicine therefrom
DE4100441A1 (en) 1991-01-09 1992-07-16 Mack Chem Pharm PROCESS FOR PREPARING 6,12-DIHYDRO-6-HYDROXY-CANNABIDIOL AND USE THEREOF FOR THE PREPARATION OF TRANS-DELTA-9-TETRAHYDROCANNABINOL
US5527819A (en) 1991-09-06 1996-06-18 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
US5635530A (en) 1991-09-12 1997-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem (3S,4S)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processors for their preparation and pharmaceutical compositions containing them
US5292899A (en) 1991-11-27 1994-03-08 Synthetic Technology Corporation Synthesis of 11-nor-Δ-9-tetrahydrocannabinol-9-carboxylic acid glucuronide
IL102082A (en) 1992-06-02 1997-07-13 Yissum Res Dev Co Antiemetic composition containing a cannabinol derivative
FR2692575B1 (en) 1992-06-23 1995-06-30 Sanofi Elf NOVEL PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5338753A (en) 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5389375A (en) 1993-05-21 1995-02-14 University Of Mississippi Stable suppository formulations effecting bioavailability of Δ9 -thc
US5440052A (en) 1993-08-06 1995-08-08 University Of Connecticut Compositions useful as a cannabinoid receptor probe
US5637589A (en) 1993-10-29 1997-06-10 University Of North Carolina At Chapel Hill Suksdorfin, analogs, compositions thereof, and methods for making and using thereof
US5521198A (en) 1993-12-21 1996-05-28 Eli Lilly And Company Methods of inhibiting autoimmune diseases
US5498419A (en) 1994-06-03 1996-03-12 Pars; Harry G. Fumarate salt of 4-(diethyl-3-(1-methyloctyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol, 4-(diethyl-amino) butyric
US5596106A (en) 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
US5532237A (en) 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
US5605906A (en) 1995-03-24 1997-02-25 Merck Frosst Canada, Inc. Cannabinoid receptor agonists
JPH11507356A (en) 1995-06-07 1999-06-29 アブマックス，インコーポレイティド Use of essential oils to enhance the bioavailability of oral pharmacological compounds
FR2742148B1 (en) 1995-12-08 1999-10-22 Sanofi Sa NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6114572A (en) 1996-11-20 2000-09-05 Hoechst Marion Roussel, Inc. Substituted phenols and thiophenols useful as antioxidant agents
CA2283797A1 (en) 1997-03-18 1998-09-24 Paul Elliot Bender Novel cannabinoid receptor agonists
US6162829A (en) 1997-10-17 2000-12-19 Atlantic Pharmaceuticals, Inc. (3R,4R)-Δ8 -tetrahydrocannabinol-11-oic acids useful as antiinflammatory agents and analgesics
AU765670B2 (en) 1998-04-03 2003-09-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Synthetic endogenous cannabinoids analogues and uses thereof
US5847128A (en) 1998-05-29 1998-12-08 Virginia Commonwealth University Water soluble derivatives of cannabinoids

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011668A2 (en) * 1995-09-11 1997-04-03 Yissum Research Development Co. Of The Hebrew University TUMOR NECROSIS FACTOR ALPHA (TNF-α) INHIBITING PHARMACEUTICALS
WO1997040006A2 (en) * 1996-04-19 1997-10-30 Cancer Research Campaign Technology Limited Phosphate mimics
WO1999052524A1 (en) * 1998-04-14 1999-10-21 The Mathilda & Terence Kennedy Institute Of Rheumatology Use of cannabinoids as anti-inflammatory agents
WO1999053917A1 (en) * 1998-04-21 1999-10-28 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Cannabinoids as antioxidants and neuroprotectants
JP2000191520A (en) * 1998-12-31 2000-07-11 Kazuo Sakuma Microbicide

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
BAEK SEUNG HWA ET AL: "Boron trifluoride etherate on silica-A modified Lewis acid reagent (VII). Antitumor activity of cannabigerol against human oral epitheloid carcinoma cells.", ARCHIVES OF PHARMACAL RESEARCH (SEOUL), vol. 21, no. 3, June 1998 (1998-06-01), pages 353 - 356, XP000957635, ISSN: 0253-6269 *
BAEK, SEUNG-HWA ET AL.: "Synthesis and antitumor activity of cannabigerol", ARCH. PHARMACAL RES., vol. 19, no. 3, 1996, pages 228 - 230, XP000979791 *
BEUTLER, J. A.: "Cytotoxic Geranyl Stilbenes from Macaranga schweinfurthii", J. NAT. PROD., vol. 61, no. 12, 1998, pages 1509 - 1512, XP000979832 *
BHARGAVA H.N.: "Potential therapeutic applications of naturally occurring and synthetic cannabinoids", GENERAL PHARMACOLOGY, vol. 9, no. 4, 1978, pages 195 - 213, XP000981417 *
BURSTEIN S. ET AL.: "Further studies on the inhibition of Leydig cell testosterone production by cannabinoids", BIOCHEMICAL PHARMACOLOGY, vol. 29, no. 14, 1980, pages 2153 - 2154, XP000979796 *
CABRAL, G. A.; VASQUEZ, R.: "Marijuana decreases macrophage antiviral and antitumor activities", ADV. BIOSCI. (OXFORD), vol. 80, 1991, pages 93 - 105, XP000981421 *
CARCHMAN, R. A. ET AL.: "Cannabinoids and neoplastic growth", MARIHUANA: CHEM., BIOCHEM., CELL. EFF., PROC. SATELL. SYMP. (1976), 1975, pages 329 - 345, XP000981329 *
DATABASE WPI Section Ch Week 200050, Derwent World Patents Index; Class B05, AN 2000-545825, XP002151974 *
ELKIN R ET AL: "DELTA-9 TETRAHYDROCANNABINOL A NOVEL TREATMENT FOR INFLAMMATORY DEMYELINATION", FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY. ANNUAL MEETING. ABSTRACTS OF PAPERS, 29 April 1987 (1987-04-29), XP002114261 *
GALLILY, R., ET AL.: "Protection against septic shock and suppression of tumor necrosis factor .alpha. and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid", J. PHARMACOL. EXP. THER., vol. 283, no. 2, 1997, pages 918 - 924, XP000981331 *
HARRIS L S ET AL: "ANTI TUMOR PROPERTIES OF CANNABINOIDS", 1976, BRAUDE, MONIQUE C AND STEPHEN SZARA (ED ) PHARMACOLOGY OF MARIHUANA,, PAGE(S) 749-762, PROCEEDINGS OF THE MEETING SAVANNAH, GA, USA, DEC 3-6, 1974 XVII+458P(VOL 1 );XVIII+404P(VOL 2 ) ILLUS RAVEN PRESS: NEW YORK, N Y, USA ISBN 0-89004-067-2 1976, XP000957683 *
HARRIS L S ET AL: "STRUCTURE ANTI TUMOR ACTIVITY OF CANNABINOIDS", PHARMACOLOGIST, vol. 17, no. 2, 1975, pages 265, XP000957659, ISSN: 0031-7004 *
HARTMANN, ROLF W. ET AL: "Antiestrogens. Synthesis and evaluation of mammary tumor inhibiting activity of 1,1,2,2-tetraalkyl-1,2-diphenylethanes", J. MED. CHEM., vol. 23, no. 8, 1980, pages 841 - 848, XP000953148 *
KAWAKAMI, Y. ET AL.: "Suppression by delta-9-tetrahydrocannabinol of interleukin-2-induced lymphocyte proliferation and lymphokine-activated killer cell activity", INT. J. IMMUNOPHARMACOL., vol. 10, no. 4, 1988, pages 485 - 488, XP000979953 *
LYMAN WD ET AL: "Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis", JOURNAL OF NEUROIMMUNOLOGY,XX,ELSEVIER SCIENCE PUBLISHERS BV, vol. 23, no. 1, 1989, pages 73 - 81, XP002114259, ISSN: 0165-5728 *
NAHAS, GABRIEL ET AL: "Inhibitor effect of 5-amylresorcinol on lymphoblastic transformation", C. R. HEBD. SEANCES ACAD. SCI., SER. D (1974), 279(19), 1607-8, 1974, XP000957652 *
NICHOLS D E ET AL: "ALLYL BENZENE ANALOGS OF DELTA-9 TETRA HYDRO CANNABINOL AS TUMOR GROWTH INHIBITORS", LIFE SCIENCES, vol. 21, no. 9, 1977, EN, pages 1245 - 1248, XP000957664, ISSN: 0024-3205 *
SINGH, SHEO B. ET AL.: "Chemistry and biology of cylindrols: novel inhibitors of Ras farnesyl-protein transferase from Cylindrocarpon lucidum", J. ORG. CHEM., vol. 61, no. 22, 1996, pages 7727 - 7727, XP000979162 *
SPECTER S ET AL: "MARIJUANA AND IMMUNOSUPPRESSION IN MAN", WATSON, R. R. (ED.). DRUGS OF ABUSE AND IMMUNE FUNCTION. IX+237P. CRC, 1990, 1990, pages 73 - 86, XP000979809 *
SPECTER S ET AL: "SUPPRESSION OF IMMUNITY BY FRIEND LEUKEMIA VIRUS AND DELTA-9 TETRAHYDROCANNABINOL", FASEB (FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY), vol. 4, no. 4, 1990, 1990, pages A1021, XP000979172, ISSN: 0892-6638 *
SRIVASTAVA M D ET AL: "DELTA 9 TETRAHYDROCANNABINOL AND CANNABIDIOL ALTER CYTOKINE PRODUCTION BY HUMAN IMMUNE CELLS", IMMUNOPHARMACOLOGY,ELSEVIER SCIENCE PUBLISHERS BV,XX, vol. 40, no. 3, October 1998 (1998-10-01), pages 179 - 185, XP000957596, ISSN: 0162-3109 *
TIMPONE J. G. ET AL.: "The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome", AIDS RES. HUM. RETROVIRUSES, vol. 13, no. 4, 1997, pages 305 - 315, XP000979121 *
WAKSMAN YAAKOV: "Cannabidiol supresses proinflammatory mediators release from rat microglial cells and hepatic Kupffer macrophages.", JOURNAL OF AUTOIMMUNITY, no. SUPPL., 1999, 2nd International Congress on Autoimmunity;Tel Aviv, Israel; March 7-11, 1999, pages 56, XP000979878, ISSN: 0896-8411 *
WATZL, B. ET AL.: "Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro", ADV. EXP. MED. BIOL., vol. 288, 1991, pages 63 - 70, XP000979761 *
WATZL, B. ET AL.: "Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro", INT. J. IMMUNOPHARMACOL., vol. 13, no. 8, 1991, pages 1091 - 1097, XP000979757 *
ZHENG, Z.M. ET AL.: "Inhibition by .DELTA.-9-tetrahydrocannabinol of tumor necrosis factor-.alpha. production by mouse and human macrophages", INT. J. IMMUNOPHARMACOL., vol. 14, no. 8, 1992, pages 1445 - 1452, XP000979762 *
ZURIER ROBERT B ET AL: "Dimethylheptyl-THC-11 OIC acid: A nonpsychoactive antiinflammatory agent with a cannabinoid template structure.", ARTHRITIS & RHEUMATISM, vol. 41, no. 1, January 1998 (1998-01-01), pages 163 - 170, XP000957594, ISSN: 0004-3591 *

Also Published As

Publication number Publication date
CN1377261A (en) 2002-10-30
AU3910700A (en) 2000-10-09
CA2367262A1 (en) 2000-09-28
WO2000056303A2 (en) 2000-09-28
HUP0203437A3 (en) 2003-07-28
IL145470A (en) 2007-06-03
EP1189603A2 (en) 2002-03-27
BR0009200A (en) 2001-12-26
HUP0203437A2 (en) 2003-05-28
CN1561990A (en) 2005-01-12
US6274635B1 (en) 2001-08-14
JP2002539246A (en) 2002-11-19
IL145470A0 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
WO2000056303A3 (en) Treatment of immune diseases
BRPI0416752A (en) pharmaceutical composition, use of one or more compounds, method for the prevention or treatment of disorders, compounds, and process for the preparation of a pharmaceutical composition
MXPA04006039A (en) Methods for the treatment of peripheral neural and vascular ailments.
BG103969A (en) C-4"-substituted macrolide derivatives
WO2004005286A3 (en) Viral inhibitors
BR0012136A (en) Highly selective norepinephrine reabsorption inhibitors and methods of using them
BR0115109A (en) Therapeutic agents and methods of their use for angiogenesis modulation
TW371628B (en) Composition for treating condyloma acuminata
WO1998056761A3 (en) Benzimidazole derivatives
WO2001021259A3 (en) Use and compositions for treating platelet-related disorders using anagrelide
EP1024145A3 (en) Novel azalides and methods of making same
BR0211119A (en) Compound, method of treating a patient who has, or preventing a patient from catching, a disease or condition, use of a compound, and method for making a compound
WO2003000343A3 (en) Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
BR0313743A (en) Benzimidazole quinolinones and uses of these
NO20011721D0 (en) N-aralkylaminotetralins as ligands for neuropeptide Y Y5 receptor
CA2505128A1 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
JO1605B1 (en) Aminopyrimidinone derivatives
PT99597B (en) METHOD FOR THE PREPARATION OF HYDROXAMIC ACID DERIVATIVES THAT INHIBITS LIPOXYGENASE
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
WO2005112967A3 (en) Anticancer activity of chios mastic gum
ES2045182T3 (en) PHYSIOLOGICALLY ACTIVE SUBSTANCES, A PROCESS FOR THE PREPARATION OF THE SAME AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
ES2094702B1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF CANCER DISEASES AND PROCEDURE FOR THEIR PREPARATION.
PT966283E (en) PHARMACEUTICAL PRODUCTS FOR THE CURE AND PREVENTION OF DISEASES RESULTING FROM LESION OF VASCULAR ENDOTHELIUM CELLS
NZ324380A (en) Therapeutic benzimidazole compounds and their use in treatment of virus infections
KR950016753A (en) New method of use of benzo [mouse (G)] quinoline

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00807895.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2367262

Country of ref document: CA

Ref document number: 2367262

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/07773

Country of ref document: ZA

Ref document number: 200107773

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2000 606208

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/00887/DE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 39107/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000918266

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000918266

Country of ref document: EP